Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Goodwill

Goodwill

3 Months Ended

Mar. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets [Text Block]

GOODWILL

Goodwill recorded as of March 31, 2015 and December 31, 2014 of $15.5 million is attributable to the 2014 acquisition of RedPath. A rollforward of the carrying value of goodwill from January 1, 2015 to March 31, 2015 is as follows:



	2015
	January 1,		Additions	Adjustments	Impairments	March 31,
RedPath	$	15,545	—	—	—	$	15,545

Other Intangible Assets

The net carrying value of the identifiable intangible assets as of March 31, 2015 is as follows:



		As of March 31, 2015
	Life	Carrying		Accumulated
	(Years)	Amount		Amortization		Net
Diagnostic assets:
Asuragen acquisition:
Thyroid	9	$	8,519	$	—	$	8,519
Pancreas	7	2,882		257		2,625
Biobank	4	1,575		246		1,329
RedPath acquisition:
Pancreas test	7	16,141		961		15,180
Barrett's test	9	18,351		—		18,351
Total		$	47,468	$	1,464	$	46,004
Diagnostic lab:
CLIA Lab	2.3	$	609	$	179	$	430

Amortization expense was $0.9 million for the three-month period ended March 31, 2015. There was no amortization expense for the quarter ended March 31, 2014. Amortization of the thyroid and Barrett's diagnostic assets will begin upon launch of the products. Estimated amortization expense for the next five years is as follows:



2015		2016		2017		2018		2019
$	5,102	$	6,358	$	6,097	$	5,949	$	5,703

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details